Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

American Journal of Nephrology

Volumn 45, Issue 2, 2017, Pages 160-169

  Wanchoo, Rimda ^a   Karam, Sabine ^c   Uppal, Nupur N ^a   Barta, Valerie S ^a   Deray, Gilbert ^d   Devoe, Craig ^b   Launay Vacher, Vincent ^d   Jhaveri, Kenar D ^a  

^a Northwell Health   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c UNIVERSITY OF BALAMAND   (Lebanon)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Acute interstitial nephritis; Ipilimumab; Nivolumab; Onconephrology; Pembrolizumab; Renal failure; Targeted therapies

Indexed keywords

CREATININE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; STEROID; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; T LYMPHOCYTE RECEPTOR;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INCIDENCE; INTERSTITIAL NEPHRITIS; KIDNEY TRANSPLANTATION; LUNG CANCER; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ACUTE KIDNEY FAILURE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG SURVEILLANCE PROGRAM; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY; NEOPLASM; PATHOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ACUTE KIDNEY INJURY; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CLINICAL TRIALS AS TOPIC; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; INCIDENCE; KIDNEY; NEOPLASMS; NEPHRITIS, INTERSTITIAL;

EID: 85009344282     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000455014     Document Type: Review

References (56)

1. Iannello A, Thompson TW, Ardolino M, Marcus A, Raulet DH: Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol 2016; 38: 52-58.
2. Smyth MJ, Dunn GP, Schreiber RD: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90: 1-50.
3. Zitvogel L, Tesniere A, Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-727.
4. Barbee MS, Ogunniyi A, Horvat TZ, Dang TO: Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015; 49: 907-937.
5. Luke JJ, Ott PA: PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 2015; 6: 3479-3492.
6. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, et al: IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011; 71: 5393-5399.
7. Tang PA, Heng DY: Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep 2013; 15: 98-104.
8. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al: Nivolumab versus docetaxel in advanced nonsquamous nonsmall-cell lung cancer. N Engl J Med 2015; 373: 1627-1639.
9. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135.
10. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
11. FDA Adverse Event Reporting System (FAERS). http://www.fda.gov/Drugs/ Guidan ceComplianceRegulatoryInformation/Surveillance/ AdverseDrugEffects/default.htm (accessed March 18, 2016).
12. Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al: Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 2016; 90: 638-647.
13. Mason NT, Khushalani NI, Weber JS, Antonia SJ, McLeod HL: Modeling the cost of immune checkpoint inhibitor-related toxicities. J Clin Oncol 2016; 34(suppl):abstr 6627.
14. Hirsch J, Wanchoo R, Devoe C, Jhaveri KD: Incidence of AKI in immune checkpoint inhibitors, single center study. J Am Soc Nephrol 2016; 27: 763.
15. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al: The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8:e53745.
16. Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD: Ipilimumab granulomatous interstitial nephritis. Am J Ther 2015; 22:e84-e87.
17. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-1717.
18. Forde PM, Rock K, Wilson G, O'Byrne KJ: Ipilimumab-induced immune-related renal failure-A case report. Anticancer Res 2012; 32: 4607-4608.
19. Fadel F, El Karoui K, Knebelmann B: Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361: 211-212.
20. Voskens C, Cavallaro A, Erdmann M, Dippel O, Kaempgen E, Schuler G, et al: Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 2012; 30:e356-e357.
21. Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, et al: Kidney injuries related to ipilimumab. Invest New Drugs 2014; 32: 769-773.
22. Kidd JM, Gizaw AB: Ipilimumab-associated minimal-change disease. Kidney Int 2016; 89: 720.
23. Barnard ZR, Walcott BP, Kahle KT, Nahed BV, Coumans JV: Hyponatremia associated with Ipilimumab-induced hypophysitis. Med Oncol 2012; 29: 374-377.
24. Chodakiewitz Y, Brown S, Boxerman JL, Brody JM, Rogg JM: Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis. Clin Neurol Neurosurg 2014; 125: 125-130.
25. Pembrolizumab package insert. http://www. accessdata.fda.gov/drugsatfda-docs/ label/2014/125514lbl.pdf (last accessed January 1, 2016).
26. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al: Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015; 21: 4286-4293.
27. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al: Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-1117.
28. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-918.
29. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387: 1540-1550.
30. Min L, Hodi FS: Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2014; 2: 15-18.
31. Shirali AC, Perazella MA, Gettinger S: Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 2016; 68: 287-291.
32. Nivolumab Package Insert. http://www.access data.fda.gov/drugsatfda-docs/label/2014/ 125554lbl.pdf (last accessed January 1, 2016).
33. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al: Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030.
34. Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, et al: Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016; 45: 7-18.
35. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33: 2004-2012.
36. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, et al: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015; 16: 257-265.
37. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al: Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030.
38. Weber JS, D'Angelo SP, Minor D, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384
39. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017.
40. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
41. Larkin J, Hodi FS, Wolchok JD: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
42. Murakami N, Borges T, Yamashita M, Riella L: Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J 2016; 9: 411-417.
43. Vandiver JW, Singer Z, Harshberger C: Severe hyponatremia and immune nephritis following an initial infusion of nivolumab. Target Oncol 2016; 11: 553-556.
44. Riella LV, Paterson AM, Sharpe AH, Chandraker A: Role of the PD-1 pathway in the immune response. Am J Transplant 2012; 12: 2575-2587.
45. Jaworska K, Ratajczak J, Huang L, Whalen K, et al: Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol 2015; 194: 325-333.
46. Menke J, Lucas JA, Zeller GC, et al: Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol 2007; 179: 7466-7477.
47. Waeckerle-Men Y, Starke A, Wuthrich RP: PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. Nephrol Dial Transplant 2007; 22: 1527-1536.
48. Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
49. Hughes J, Vudattu N, Sznol M, et al: Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015; 38:e55-e57.
50. Spanou Z, Keller M, Britschgi M, et al: Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 2006; 17: 2919-2927.
51. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH: Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 2014; 32:e69-e71.
52. Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, et al: Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 2016; 374: 896-898.
53. Alhamad T, Venkatachalam K, Linette GP, Brennan DC: Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant 2016; 16: 1332-1333.
54. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J: Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol 2016; 27: 1135-1137.
55. Boils CL, Aljadir DN, Cantafio AW: Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. Am J Transplant 2016; 16: 2496-2497.
56. Barnett R, Barta VS, Jhaveri KD: Preserved renal allograft function while using the PD-1 pathway inhibitor nivolumab. N Engl J Med 2017; 376: 191-192.